background:
JAML is a 394 amino acid single-pass type I membrane protein and novel adhesion molecule with localization at the cell plasma membrane in regions of cell-to-cell contact but not free cell borders, implying that JAML participates in homophilic interactions. JAML belongs to the immunoglobulin superfamily and is expressed in peripheral blood leukocytes, bone marrow, spleen, lymph nodes and fetal thymus, liver and spleen. JAML assists in the migration of leukocytes through endothelilal and epithelial tissues, mediates binding with CAR (coxsackie and adenovirus receptor) via its Ig-like SLVtype domain 2, and strengthens the binding of leukocytes to endothelial cells. Consisting of a transmembrane segment, cytoplasmic tail, 19-amino acid signal peptide and two extracellular immunoglobulin-like domains, JAML also undergoes alternative splicing resulting in three isoforms and is encoded by a gene mapping to human chromosome 11q23.3.
Function:
May function in transmigration of leukocytes through epithelial and endothelial tissues. Expressed at the plasma membrane of polymorphonuclear leukocytes, it mediates adhesive interactions with CXADR, a protein of the junctional complex of epithelial cells. Enhances myeloid leukemia cell adhesion to endothelial cells.
Subcellular Location:
Cell junction. Cell membrane. Localized at the plasma membrane in areas of cell-cell contacts and at the cell surface of PMN.
Tissue Specificity:
Expression is restricted to the hematopoietic tissues with the exception of liver. Expressed in fetal liver, spleen and thymus.
Similarity:
Belongs to the immunoglobulin superfamily.
Contains 2 Ig-like SLVtype (immunoglobulin-like) domains.
Database links:
Entrez Gene: 120425 Human
Entrez Gene: 270152 Mouse
Entrez Gene: 315610 Rat
Omim: *609770 Human
SwissProt: Q86YT9 Human
SwissProt: Q80UL9 Mouse
Unigene: 16291 Human
Unigene: 190461 Mouse
Unigene: 21010 Rat
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
|
|
